Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia

Expert Review of Anticancer Therapy

Volumn 8, Issue 5, 2008, Pages 785-798

  Lekakis, Lazaros ^a   de Lima, Marcos ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Altogeneic stem cell transplantation; Nonmyetoablative; Reduted intensity conditioning

Indexed keywords

ALEMTUZUMAB; AMIFOSTINE; AMSACRINE; ANTHRACYCLINE; AZACITIDINE; BENZIMIDAVIR; BUSULFAN; CALCINEURIN; CANCER VACCINE; CARMUSTINE; CLADRIBINE; CLOFARABINE; CLORETAZINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOTOXIC AGENT; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PALIFERMIN; PENTOSTATIN; RAPAMYCIN; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; DONOR; DRUG MEGADOSE; DRUG TOLERABILITY; ELDERLY CARE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; LOW DRUG DOSE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PROGNOSIS; REDUCED INTENSITY CONDITIONING; REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION; AGED; ALLOTRANSPLANTATION; METHODOLOGY;

AGED; ANTINEOPLASTIC AGENTS; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; LEUKEMIA, MYELOID, ACUTE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 45849102069     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.5.785     Document Type: Review

References (82)

1. Farag SS, Archer KJ, Mrozek K et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108(1), 63-73 (2006).
2. Estey E, de Lima M, Tibes R et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109(4), 1395-1400 (2007).
3. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch. Intern. Med. 162(14), 1597-1603 (2002).
4. Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood 107(9), 3481-3485 (2006).
5. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3), 555-562 (1990).
6. Porter DL, Antin JH. Donor leukocyte infusions in myeloid malignancies: new strategies. Best Pract. Res. Clin. Haematol. 19(4), 737-755 (2006).
7. Schmid C, Labopin M, Nagler A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J. Clin. Oncol. 25(31), 4938-4945 (2007).
8. Ringden O, Labopin M, Gorin NC et al. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br. J. Haematol. 111(4), 1130-1137 (2000).
9. Baron F, Maris MB, Sandmaier BM et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J. Clin. Oncol. 23(9), 1993-2003 (2005).
10. Martino R, Caballero MD, Simon JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100(6), 2243-2245 (2002).
11. Shlomchik WD. Graft-versus-host disease. Nat. Rev. Immunol. 7(5), 340-352 (2007).
12. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int. J. Hematol. 78(3), 181-187 (2003).
13. Couriel DR, Saliba RM, Giralt S et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol. Blood Marrow Transplant. 10(3), 178-185 (2004).
14. Valcarcel D, Martino R, Caballero D et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J. Clin. Oncol. 26(4), 577-584 (2008).
15. Sorror ML, Sandmaier BM, Storer BE et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J. Clin. Oncol. 25(27), 4246-4254 (2007).
16. Aoudjhane M, Labopin M, Gorin NC et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19(12), 2304-2312 (2005).
17. Champlin R, Khouri I, Shinioni A et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br. J. Haematol. 111 (1), 18-29 (2000).
18. Storb R. Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract. Res. Clin. Haematol. 20(1), 85-90 (2007).
19. Niederwieser D, Lange T, Cross M, Basara N, Al-Ali H. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract. Res. Clin. Haematol. 19(4), 825-838 (2006).
20. Blaise D, Vey N, Faucher C, Mohty M. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 92(4), 533-541 (2007).
21. Appelbaum FR, Kopecky KJ, Tallman MS et al. The clinical spectrum of adult acute myeloid associated with core binding factor translocations. Br. J. Haematol. 135(2), 165-173 (2006).
22. Borssel N, Leroy H, Brethon B et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20(6), 965-970 (2006).
23. Marcucci G, Mrozek K, Ruppert AS et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J. Clin. Oncol. 23(24), 5705-5717 (2005).
24. Mrozek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 169-177 (2006).
25. Schlenk RF, Benner A, Krauter J et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J. Clin. Oncol. 22(18), 3741-3750 (2004).
26. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92(7), 2322-2333 (1998).
27. Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96(13), 4075-4083 (2000).
28. Byrd JC, Mrozek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13), 4325-4336 (2002).
29. Burnett AK, Wheatley K, Goldstone AH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br. J. Haematol. 118(2), 385-400 (2002).
30. Farag SS, Ruppert AS, Mrozek K et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J. Clin. Oncol. 23(3), 482-493 (2005).
31. Oran B, Giralt S, Saliba R et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol. Blood Marrow Transplant. 13(4), 444-462 (2007).
32. Baldus CD, Mrozek K, Marcucci G, Bloomfield CD. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. Br. J. Haematol. 137(5), 387-400 (2007).
33. Marcucci G, Maharry K, Whitman SP et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J. Clin. Oncol. 25(22), 3337-3343 (2007).
34. Konoplev S, Rassidakis GZ, Estey E et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 109(6), 1152-1156 (2007).
35. Thiede C, Koch S, Creutzig E et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107(10), 4011-4020 (2006).
36. Frohling S, Schlenk RF, Stolze I et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J. Clin. Oncol. 22(4), 624-633 (2004).
37. Cornelissen JJ, van Putten WL, Verdonck LF et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adulm benefits for whom? Blood 109(9), 3658-3666 (2007).
38. Suciu S, Mandelli F, de Witte T et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/ GIMEMAAML-10 trial. Blood 102(4), 1232-1240 (2003).
39. Reiffers J, Stoppa AM, Attal M et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 10(12), 1874-1882 (1996).
40. Matthews JP, Bishop JF, Young GA et al. Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. Br. J. Haematol. 13(3), 727-736 (2001).
41. Grimwade D, Walker H, Harrison G et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98(5), 1312-1320 (2001).
42. de Lima M, Anagnostopoulos A, Munsell M et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104(3), 865-872 (2004).
43. Lazarus HM, Rowe JM. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 20(10), 1673-1682 (2006).
44. Shimoni A, Hardan I, Shem-Tov N et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20(2), 322-328 (2006).
45. Stelljes M, Bornhauser M, Kroger M et al. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood 106(9), 3314-3321 (2005).
46. Hegenbart U, Niederwieser D, Sandmaier BM et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J. Clin. Oncol. 24(3), 444-453 (2006).
47. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequencial regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol. 23(24), 5675-5687 (2005).
48. Tauro S, Craddock C, Peggs K et al. Allogeneic stem-cell trans plantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 23(36), 9387-9393 (2005).
49. Martino R, Ho A, Sierra J et al. Reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation with or without alemtuzumab in acute myelogenous leukaemia, and myelodysplastic syndromes: comparison between two prospective studies using fludarabine and oral busulphan. Bone Marrow Transplant. 33, S11-S12 (2004).
50. Martino R, Iacobelli S, Brand R et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108(3), 836-846 (2006).
51. Scott BL, Sandmaier BM, Storer B et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20(1), 128-135 (2006).
52. de Lima M, Couriel D, Thall PF et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104(3), 857-864 (2004).
53. Alyea EP, Kim HT, Ho V et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol. Blood Marrow Transplant. 12(10), 1047-1055 (2006).
54. Sorror ML, Giralt S, Sandmaier BM et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission combined EHCRC and MDACC experiences. Blood 110(13), 4606-4613 (2007).
55. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT) specific comorbidity index: a riew tool for risk assessment before allogeneic HCT. Blood 106(8), 2912-2919 (2005).
56. Alamo J, Shahjahan M, Lazarus HM, de Lima M, Giralt SA. Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplant. 36(6), 475-479 (2005).
57. Platzbecker U, Thiede C, Fussel M et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 20(4), 707-714 (2006).
58. Miller KB, Roberts TF, Chan G et al. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant. 33(9), 881-889 (2004).
59. Lowsky R, Takahashi T, Liu YP et al. Protective conditioning for acute graft-versus-host disease. N. Engl. J. Med. 353(13), 1321-1331 (2005).
60. Ringhoffer M, Blumstein N, Neumaier B et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a Phase I-II study. Br. J. Haematol. 130(4), 604-613 (2005).
61. Claxton DF, Ehmann C, Rybka W. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br. J. Haematol. 130(2), 256-264 (2005).
62. de Lima M, Champlin RE, Thall PF et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia (2007) (Epub ahead of print).
63. + acute myeloid leukemia. Biol Blood Marrow Transplant. 13(2), 30-31 (2007).
64. Pagel JM, Appelbaum FR, Eary JF et al. 131I-anti-CD45 antibody plus busulfan and cyctophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107(5), 2184-2191 (2006).
65. Leen M, Myers CD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12(10), 1160-1166 (2006).
66. Rusakiewicz S, Molldrem JJ. Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr. Opin. Immunol. 18(5), 599-604 (2006).
67. Winston DJ, Young JA, Pullarkat V et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem-cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled; dose-ranging study. Blood (2008) (Epub ahead of print).
68. Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Elininger G. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J. Clin. Oncol. 24(5), 790-797 (2006).
69. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98(5), 1302-1311 (2001).
70. van der Holt B, Lowenberg B, Burnett AK et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106(8), 2646-2654 (2005).
71. Anderson JE, Kopecky KJ, Willman CL et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 100(12), 3869-3876 (2002).
72. Rowe JM, Neuberg D, Friedenberg W et al. A Phase III study of three induction regimens and of printing with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103(2), 479-485 (2004).
73. Estey EH, Thall PF, Giles FJ et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 99(12), 4343-4349 (2002).
74. van Besien K, Artz A, Smith S et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol. 23(24), 5728-5738 (2005).
75. Gomez-Nunez M, Martino R, Caballero MD et al. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial. Bone Marrow Transplant. 33(5), 477-482 (2004).
76. Shimoni A, Kroger N, Zabelina T et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 19(1), 7-12 (2005).
77. Hamaki T, Kami M, Kim SW et al. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. Bone Marrow Transplant. 33(9), 891-900 (2004).
78. Spyridonidis A, Bertz H, Ihorst G, Grullich C, Finke J. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies. Blood 105(10), 4147-4148 (2005).
79. Corradini P, Zallio P, Mariotti J et al. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J. Clin. Oncol. 23(27), 6690-6698 (2005).
80. Hallemeier C, Girgis M, Blum W et al. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biol. Blood Marrow Transplant. 10(5), 310-319 (2004).
81. Sayer HG, Kroger M, Beyer J et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 31(12), 1089-1095 (2003).
82. Alyea EP, Kim HT, Ho V et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105(4), 1810-1814 (2005).